BRPI9915552B8 - pirimidinas inibidoras da reprodução do hiv - Google Patents

pirimidinas inibidoras da reprodução do hiv

Info

Publication number
BRPI9915552B8
BRPI9915552B8 BRPI9915552A BR9915552A BRPI9915552B8 BR PI9915552 B8 BRPI9915552 B8 BR PI9915552B8 BR PI9915552 A BRPI9915552 A BR PI9915552A BR 9915552 A BR9915552 A BR 9915552A BR PI9915552 B8 BRPI9915552 B8 BR PI9915552B8
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
nhc
amino
alkyloxycarbonyl
Prior art date
Application number
BRPI9915552A
Other languages
English (en)
Other versions
BR9915552B1 (pt
BR9915552A (pt
Inventor
De Corte Bart
Yung Ho Chih
William Ludovici Donald
Heeres Jan
Jeanne Alfons Vans Aken Koen
Jozef Lodenwijk Marcel Andries Koenraad
Maria Henricus Koymans Lucien
Rene De Jonge Marc
Joseph Kukla Michael
Adriaan Jan Janssen Paul
W Kavash Robert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9915552(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9915552A publication Critical patent/BR9915552A/pt
Publication of BR9915552B1 publication Critical patent/BR9915552B1/pt
Publication of BRPI9915552B8 publication Critical patent/BRPI9915552B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

patente de invenção: <b>"pirimidinas inibidoras da reprodução do hiv"<d>. esta invenção trata do uso de compostos da fórmula (i), os n-óxidos, os sais de adição farmaceuticamente aceitáveis, aminas qua-ternárias e a sua forma estereoquimicamente isoméricas, onde a^ 1^=a^ 2^=a^ 3^=a^ 4^-forma um fenila, piridinila, pirimidinila, piridazinila ou pirazinila com o grupo vinila agregado; n é 0 a 4; e onde possível 5; r^ 1^ é hidrogênio, arila, formila, c~ 1-6~alquilcarbonila, c~ 1-6~alquila, c~ 1-6~alquiloxicarbonila, c~ 1-6~ alquila substituída ou c~ 1-6~alquilóxic~ 1-6~ alquilcarbonila substituída; cada r3 independentemente é hidróxi, halo, opcionalmente substituído c~ 1-6~ alquila, c~ 2-6~alquenila ou c~ 2-6~-alquinila, c~ 3-7~cicloalquila, c~ 1-6~alquilóxi, c~ 1-6~alquiloxicarbonila, carboxila, ciano, nitro, amino, mono- ou di(c~ 1-6~alquila)amino, polihalometila, polihalo-metilóxi, polihalometiltio, -s(=o)~ p~r^ 6^, -nh-s(=o)~ p~r^ 6^, - c(=o)r^ 6^, -nhc(=o)h, -c(=o)nhnh~ 2~, -nhc(=o)r^ 6^, -c(=nh)r^ 6^ ou um anel heterocíclico de 5 membros; p é 1 ou 2; l é opcionalmente substituído c~ 1-10~ alquila, c~ 2-10~ alquenila ou c~ 3-7~ cicloalquila; ou l é -x-r^ 3^ onde r^ 3^ é fenila, piridinila, pirimidinila, pirazinila ou piridazinila, opcionalmente substituída x é -nr^ 1^-, -nh-nh-, -n=n, -o-, c(=o)-choh-, -s-, -s(=o)- ou -s(=o)~ 2~-; q é hidrogênio, c~ 1-6~alquila, halo, polihalo-c~ 1-6~alquila ou um grupo opcionalmente substituído; y representa hidróxi, halo c~ 3-7~cicloalquila, c~ 1-6~alquila, c~ 2-6~ alquenila ou c~ 2-6~ alquila, opcionalmente substituída, c~ 1-6~alquilóxi, c~ 1-6~ alquiloxicarbonila, carbonila, ciano, nitro, amino, mono-ou di(c~ 1-6~ alquila)amino, polihalo-metila, polihalometilóxi, polihalometitio, -s(=o)~ p~r^ 6^, -nh-s(=o)~ p~r^ 6^, -c(=o)r^ 6^, -nhc(=o)h, -c(=o)nhnh~ 2~, -nhc(=o)r^ 6^, -c(=nh)r^ 6^ ou arila; arila é fenila opcionalmente substituído; het é um radical heterocíclico opcionalmente substituída; para a fabricação de um medicamento para o tratamento de doentes sofrendo da infecção do hiv (vírus da imunodeficiência humana).
BRPI9915552A 1998-11-10 1999-09-24 pirimidinas inibidoras da reprodução do hiv BRPI9915552B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (3)

Publication Number Publication Date
BR9915552A BR9915552A (pt) 2001-08-14
BR9915552B1 BR9915552B1 (pt) 2013-11-19
BRPI9915552B8 true BRPI9915552B8 (pt) 2021-05-25

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915552A BRPI9915552B8 (pt) 1998-11-10 1999-09-24 pirimidinas inibidoras da reprodução do hiv

Country Status (41)

Country Link
US (5) US6878717B2 (pt)
EP (2) EP1002795B1 (pt)
JP (1) JP3635238B2 (pt)
KR (1) KR100658489B1 (pt)
CN (1) CN1214013C (pt)
AP (1) AP1683A (pt)
AR (1) AR024227A1 (pt)
AT (2) ATE233740T1 (pt)
AU (2) AU762523C (pt)
BG (1) BG65103B1 (pt)
BR (1) BRPI9915552B8 (pt)
CA (1) CA2350801C (pt)
CY (1) CY2008021I2 (pt)
CZ (1) CZ301367B6 (pt)
DE (3) DE122009000003I1 (pt)
DK (1) DK1002795T3 (pt)
EA (1) EA004049B1 (pt)
EE (1) EE05086B1 (pt)
ES (2) ES2338760T3 (pt)
FR (1) FR09C0004I2 (pt)
HK (1) HK1048817B (pt)
HR (2) HRP20010161B9 (pt)
HU (2) HU230394B1 (pt)
ID (1) ID28376A (pt)
IL (2) IL143023A0 (pt)
LT (1) LTC1002795I2 (pt)
LU (1) LU91528I2 (pt)
MY (1) MY121108A (pt)
NL (1) NL300373I2 (pt)
NO (3) NO318801B1 (pt)
NZ (1) NZ511116A (pt)
OA (1) OA11674A (pt)
PL (1) PL204427B1 (pt)
PT (1) PT1002795E (pt)
SI (1) SI1002795T1 (pt)
SK (2) SK287270B6 (pt)
TR (1) TR200101306T2 (pt)
TW (1) TWI238161B (pt)
UA (1) UA70966C2 (pt)
WO (1) WO2000027825A1 (pt)
ZA (1) ZA200103769B (pt)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9915552B8 (pt) * 1998-11-10 2021-05-25 Janssen Pharmaceutica Nv pirimidinas inibidoras da reprodução do hiv
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
SI1225874T1 (sl) 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Protivirusne trdne disperzije
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
ES2559273T3 (es) 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
CN1302418C (zh) * 2000-11-01 2007-02-28 斯雷普内姆斯·Com公司 集成注册机构的互联网域名获取系统
JP4291135B2 (ja) 2001-05-29 2009-07-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
HUP0402330A3 (en) 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof
US7514445B2 (en) 2001-11-01 2009-04-07 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MY140390A (en) 2002-03-13 2009-12-31 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003222310B2 (en) * 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
CA2686429C (en) 2002-08-09 2010-11-16 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
MXPA05005547A (es) * 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
HRP20050688B1 (hr) 2003-02-07 2017-03-24 Janssen Pharmaceutica N.V. Derivati pirimidina za sprječavanje hiv infekcije
WO2004074266A1 (en) * 2003-02-07 2004-09-02 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
ATE433447T1 (de) * 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1648467B1 (en) 2003-07-17 2018-03-21 Janssen Sciences Ireland UC Process for preparing particles containing an antiviral
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
CN100475815C (zh) * 2003-09-25 2009-04-08 詹森药业有限公司 抑制hiv复制的嘌呤衍生物
EP1728186A2 (en) 2004-03-02 2006-12-06 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
SG156687A1 (en) 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2575002C (en) 2004-08-10 2015-01-20 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazin-6-one derivatives
US8946248B2 (en) * 2004-09-30 2015-02-03 Janssen R&D Ireland HIV inhibiting 5-substituted pyrimidines
CA2577467C (en) * 2004-09-30 2013-05-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
BRPI0515935B8 (pt) * 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
EP1812069A2 (en) * 2004-11-08 2007-08-01 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and etravirine
DK1814878T3 (da) 2004-11-24 2012-05-07 Rigel Pharmaceuticals Inc Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
PL1856135T3 (pl) 2005-01-19 2010-05-31 Rigel Pharmaceuticals Inc Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie
WO2006079656A1 (en) * 2005-01-27 2006-08-03 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
ATE398613T1 (de) 2005-02-16 2008-07-15 Astrazeneca Ab Chemische verbindungen
CN101119976B (zh) * 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
ES2347815T3 (es) * 2005-03-04 2010-11-04 Tibotec Pharmaceuticals 2-(4-cianofenil)-6-hidroxilaminopirimidinas inhibidoras de hiv.
KR20080015409A (ko) 2005-05-16 2008-02-19 아스트라제네카 아베 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체
HRP20131133T1 (hr) 2005-05-26 2014-01-03 Janssen R&D Ireland Postupak za dobivanje 4-[(1,6-dihidro-6-okso-2-pirimidinil)amino benzonitrila
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
WO2007044565A2 (en) * 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
US8119650B2 (en) 2006-01-19 2012-02-21 Janssen Pharmaceutica N.V. Aminophenyl derivatives as novel inhibitors of histone deacetylase
DK1981875T3 (da) 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
CN101410394B (zh) 2006-03-30 2012-02-08 泰博特克药品有限公司 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶
WO2007113254A1 (en) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
SI2029110T1 (sl) * 2006-06-06 2012-01-31 Tibotec Pharm Ltd Z razprševanjem posušeni pripravki TMC125
ATE552829T1 (de) 2006-06-19 2012-04-15 Alpharma Pharmaceuticals Llc Pharmazeutische zusammensetzungen
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
ES2624593T3 (es) 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
KR20090094084A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5,6-치환된 피리미딘
EP2114901B1 (en) 2006-12-29 2014-04-09 Janssen R&D Ireland Hiv inhibiting 6-substituted pyrimidines
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP3210609A1 (en) 2008-05-21 2017-08-30 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
WO2010112411A1 (en) 2009-03-30 2010-10-07 Tibotec Pharmaceuticals Co-crystal of etravirine and nicotinamide
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
RU2556986C2 (ru) * 2009-06-22 2015-07-20 Эмкьюар Фармасьютикалз Лимитед Способ синтеза диарилпиримидинового ненуклеозидного ингибитора обратной транскриптазы
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
US8598341B2 (en) 2010-06-28 2013-12-03 Hetero Research Foundation Process for etravirine intermediate and polymorphs of etravirine
EP2603081B1 (en) 2010-08-10 2016-10-05 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
CA3017869C (en) 2010-11-10 2021-07-27 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
WO2012147104A1 (en) 2011-04-26 2012-11-01 Mylan Laboratories Ltd Novel process for the preparation of etravirine
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
PL2748166T3 (pl) 2011-08-23 2019-05-31 Asana Biosciences Llc Związki pirimido-pirydazynonowe oraz ich zastosowanie
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
WO2013138502A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2014068588A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of etravirine and its intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
EP2934501A4 (en) 2012-12-21 2016-06-01 Verlyx Pharma Inc USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
DK3242666T5 (da) 2015-01-06 2025-01-20 Arena Pharm Inc Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CA3060316A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4694009A (en) * 1984-06-25 1987-09-15 Ciba-Geigy Corporation Pesticidal compositions
HU206328B (en) 1988-03-31 1992-10-28 Mitsubishi Chem Ind Process for producing 6-substituted pyrimidine derivatives and antiviral phqrmaceutical compositions containing them as active components
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
PL189122B1 (pl) 1995-11-23 2005-06-30 Janssen Pharmaceutica Nv Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
PL202675B1 (pl) * 1998-03-27 2009-07-31 Janssen Pharmaceutica Nv Zastosowanie hamującej HIV, pochodnej pirymidyny, pochodna pirymidyny i sposób jej wytwarzania oraz kompozycja farmaceutyczna
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
BRPI9915552B8 (pt) * 1998-11-10 2021-05-25 Janssen Pharmaceutica Nv pirimidinas inibidoras da reprodução do hiv
ES2559273T3 (es) * 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH

Also Published As

Publication number Publication date
AU2011200708A1 (en) 2011-03-10
EP1270560A1 (en) 2003-01-02
ES2338760T3 (es) 2010-05-12
AP1683A (en) 2006-11-29
HUP0104177A3 (en) 2003-01-28
ZA200103769B (en) 2002-08-12
AR024227A1 (es) 2002-09-25
AU6200899A (en) 2000-05-29
HK1048817A1 (en) 2003-04-17
JP2002529456A (ja) 2002-09-10
OA11674A (en) 2005-01-12
NO318801B1 (no) 2005-05-09
TWI238161B (en) 2005-08-21
NL300373I2 (nl) 2009-04-01
CA2350801A1 (en) 2000-05-18
NO2021015I1 (no) 2021-03-29
MY121108A (en) 2005-12-30
HU227453B1 (en) 2011-06-28
DE69905683T2 (de) 2004-03-18
SI1002795T1 (en) 2003-10-31
CZ20011533A3 (cs) 2001-10-17
US20050288278A1 (en) 2005-12-29
CY2008021I1 (el) 2010-07-28
HRP20080359B1 (hr) 2016-01-01
ES2193664T3 (es) 2003-11-01
FR09C0004I2 (fr) 2010-06-11
NO2009003I1 (no) 2009-03-09
EP1270560B1 (en) 2010-01-13
BG65103B1 (bg) 2007-02-28
EE05086B1 (et) 2008-10-15
HRP20010161A2 (en) 2002-02-28
ATE455107T1 (de) 2010-01-15
HK1048817B (en) 2010-04-09
HU230394B1 (hu) 2016-04-28
IL169949A (en) 2011-02-28
US8003789B2 (en) 2011-08-23
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
PL204427B1 (pl) 2010-01-29
NO20011696D0 (no) 2001-04-04
HUP0104177A2 (hu) 2002-03-28
BG105418A (en) 2001-11-30
US20110263625A1 (en) 2011-10-27
TR200101306T2 (tr) 2001-10-22
ATE233740T1 (de) 2003-03-15
CN1322198A (zh) 2001-11-14
DE122009000003I1 (de) 2009-05-20
NL300373I1 (nl) 2009-03-02
HRP20010161B9 (hr) 2014-10-24
IL143023A0 (en) 2002-04-21
US20080176880A1 (en) 2008-07-24
US20040039005A1 (en) 2004-02-26
UA70966C2 (uk) 2004-11-15
JP3635238B2 (ja) 2005-04-06
PL347586A1 (en) 2002-04-08
EA200100536A1 (ru) 2002-02-28
CY2008021I2 (el) 2010-07-28
HK1025330A1 (en) 2000-11-10
CZ301367B6 (cs) 2010-02-03
US6878717B2 (en) 2005-04-12
FR09C0004I1 (pt) 2009-02-27
PT1002795E (pt) 2003-07-31
BR9915552B1 (pt) 2013-11-19
US7037917B2 (en) 2006-05-02
LTC1002795I2 (lt) 2021-06-10
US8530655B2 (en) 2013-09-10
EP1002795A1 (en) 2000-05-24
AU762523B2 (en) 2003-06-26
EE200100252A (et) 2002-10-15
WO2000027825A1 (en) 2000-05-18
NZ511116A (en) 2003-08-29
CA2350801C (en) 2008-05-20
SK6032001A3 (en) 2002-01-07
DE69941934D1 (de) 2010-03-04
LTPA2008016I1 (lt) 2021-04-26
NO2009003I2 (no) 2010-06-07
LU91528I9 (pt) 2019-01-02
CN1214013C (zh) 2005-08-10
KR20010075235A (ko) 2001-08-09
EP1002795B1 (en) 2003-03-05
EA004049B1 (ru) 2003-12-25
HRP20080359A2 (en) 2008-12-31
HRP20010161B1 (en) 2009-03-31
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
KR100658489B1 (ko) 2006-12-18
NO20011696L (no) 2001-04-04
BR9915552A (pt) 2001-08-14
AU762523C (en) 2004-02-12
LU91528I2 (fr) 2009-04-20
SK287269B6 (sk) 2010-05-07

Similar Documents

Publication Publication Date Title
BRPI9915552B8 (pt) pirimidinas inibidoras da reprodução do hiv
AP1610A (en) HIV replication inhibiting pyrimidines.
MXPA05008364A (es) Derivados de pirimidina para la prevencion de una infeccion por vih.
CA2324919A1 (en) Hiv inhibiting pyrimidine derivatives
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BG106526A (en) Therapeutic quinazoline derivatives
MY138308A (en) Hiv replication inhibiting pyrimidines and triazines
CY1110979T1 (el) Παραγωγα κιναζολινης ως αναστολεις αγγειογενεσης και ενδιαμεσες ενωσεις αυτων
CA2324921A1 (en) Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
ATE233754T1 (de) Diphenyl-piperidin derivate
ATE300178T1 (de) Herbizide wirkstoffkombinationen
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
ES2196332T3 (es) Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos.
YU39503A (sh) Derivati pirimidina
BR9915176A (pt) Derivados de triazina dissubstituìdos nas posições 2,4
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
CY1125571T1 (el) Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv
UA81654C2 (ru) Пиримидины и триазины, которые ингибируют репликацию вич

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/09/2019